Repligen
RGEN
#2297
Rank
โ‚น782.68 B
Marketcap
โ‚น13,876
Share price
1.23%
Change (1 day)
30.55%
Change (1 year)
Categories

Repligen (RGEN) - Total liabilities

Total liabilities on the balance sheet as of March 2026 : โ‚น77.89 Billion

According to Repligen 's latest financial reports the company's total liabilities are โ‚น77.89 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Repligen - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31โ‚น75.72 B3.01%
2024-12-31โ‚น73.51 B1.93%
2023-12-31โ‚น72.12 B40.37%
2022-12-31โ‚น51.37 B13.48%
2021-12-31โ‚น45.27 B65.64%
2020-12-31โ‚น27.33 B12.62%
2019-12-31โ‚น24.27 B118.23%
2018-12-31โ‚น11.12 B14.61%
2017-12-31โ‚น9.70 B18.85%
2016-12-31โ‚น8.16 B423.06%
2015-12-31โ‚น1.56 B48.72%
2014-12-31โ‚น1.04 B15.11%
2013-12-31โ‚น0.91 B29.24%
2012-12-31โ‚น0.70 B
2011-03-31โ‚น0.23 B-2.07%
2010-03-31โ‚น0.23 B0.97%
2009-03-31โ‚น0.23 B23.42%
2008-03-31โ‚น0.18 B24.18%
2007-03-31โ‚น0.15 B7.59%
2006-03-31โ‚น0.14 B-1.61%
2005-03-31โ‚น0.14 B35.72%
2004-03-31โ‚น0.10 B-0.37%
2003-03-31โ‚น0.10 B-18.04%
2002-03-31โ‚น0.13 B122.07%
2001-03-31โ‚น58.62 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Pfizer
PFE
โ‚น11.063 T 14,102.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
โ‚น5.778 T 7,317.83%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
โ‚น10.396 T 13,246.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น6.264 T 7,942.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚น7.77 B-90.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚น112.12 B 43.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚น141.46 B 81.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
โ‚น43.91 B-43.62%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚น224.53 B 188.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
โ‚น447.57 B 474.57%๐Ÿ‡บ๐Ÿ‡ธ USA